Literature DB >> 22026995

BMPs and their clinical potentials.

Meejung Kim1, Senyon Choe.   

Abstract

Bone morphogenetic protein (BMP) signaling in diseases is the subject of an overwhelming array of studies. BMPs are excellent targets for treatment of various clinical disorders. Several BMPs have already been shown to be clinically beneficial in the treatment of a variety of conditions, including BMP-2 and BMP-7 that have been approved for clinical application in nonunion bone fractures and spinal fusions. With the use of BMPs increasingly accepted in spinal fusion surgeries, other therapeutic approaches targeting BMP signaling are emerging beyond applications to skeletal disorders. These approaches can further utilize next-generation therapeutic tools such as engineered BMPs and ex vivo- conditioned cell therapies. In this review, we focused to provide insights into such clinical potentials of BMPs in metabolic and vascular diseases, and in cancer. [BMB reports 2011; 44(10): 619-634].

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22026995      PMCID: PMC3423198          DOI: 10.5483/BMBRep.2011.44.10.619

Source DB:  PubMed          Journal:  BMB Rep        ISSN: 1976-6696            Impact factor:   4.778


  211 in total

Review 1.  Metastasis to bone: causes, consequences and therapeutic opportunities.

Authors:  Gregory R Mundy
Journal:  Nat Rev Cancer       Date:  2002-08       Impact factor: 60.716

Review 2.  Cross talk between Smad, MAPK, and actin in the etiology of pulmonary arterial hypertension.

Authors:  James West
Journal:  Adv Exp Med Biol       Date:  2010       Impact factor: 2.622

3.  Human BMP-7/OP-1 induces the growth and differentiation of adipocytes and osteoblasts in bone marrow stromal cell cultures.

Authors:  T L Chen; W J Shen; F B Kraemer
Journal:  J Cell Biochem       Date:  2001       Impact factor: 4.429

4.  Differential roles of Smad1 and p38 kinase in regulation of peroxisome proliferator-activating receptor gamma during bone morphogenetic protein 2-induced adipogenesis.

Authors:  Kenji Hata; Riko Nishimura; Fumiyo Ikeda; Kenji Yamashita; Takuma Matsubara; Takashi Nokubi; Toshiyuki Yoneda
Journal:  Mol Biol Cell       Date:  2003-02       Impact factor: 4.138

Review 5.  Skeletal complications of malignancy.

Authors:  R E Coleman
Journal:  Cancer       Date:  1997-10-15       Impact factor: 6.860

6.  The positive correlation between gene expression of the two angiogenic factors: VEGF and BMP-2 in lung cancer patients.

Authors:  Magdalena Bieniasz; Katarzyna Oszajca; Mak Eusebio; Jacek Kordiak; Jacek Bartkowiak; Janusz Szemraj
Journal:  Lung Cancer       Date:  2009-03-25       Impact factor: 5.705

7.  Osteogenic protein-1 (bone morphogenetic protein-7) reduces severity of injury after ischemic acute renal failure in rat.

Authors:  S Vukicevic; V Basic; D Rogic; N Basic; M S Shih; A Shepard; D Jin; B Dattatreyamurty; W Jones; H Dorai; S Ryan; D Griffiths; J Maliakal; M Jelic; M Pastorcic; A Stavljenic; T K Sampath
Journal:  J Clin Invest       Date:  1998-07-01       Impact factor: 14.808

8.  Bone morphogenetic protein-4 inhibits heat-induced apoptosis by modulating MAPK pathways in human colon cancer HCT116 cells.

Authors:  Haiyun Deng; T S Ravikumar; Weng-Lang Yang
Journal:  Cancer Lett       Date:  2007-07-20       Impact factor: 8.679

Review 9.  Bone morphogenetic proteins and cancer: review of the literature.

Authors:  Jayesh P Thawani; Anthony C Wang; Khoi D Than; Chia-Ying Lin; Frank La Marca; Paul Park
Journal:  Neurosurgery       Date:  2010-02       Impact factor: 4.654

10.  A paracrine requirement for hedgehog signalling in cancer.

Authors:  Robert L Yauch; Stephen E Gould; Suzie J Scales; Tracy Tang; Hua Tian; Christina P Ahn; Derek Marshall; Ling Fu; Thomas Januario; Dara Kallop; Michelle Nannini-Pepe; Karen Kotkow; James C Marsters; Lee L Rubin; Frederic J de Sauvage
Journal:  Nature       Date:  2008-08-27       Impact factor: 49.962

View more
  35 in total

1.  Possible role of BMP-4 in the hyper-pigmentation of psoriatic plaques after anti-TNF-α treatment.

Authors:  Luisa Di Costanzo; Emanuele Scala; Giuseppina Caiazzo; Serena Lembo; Rita Marino; Matteo Megna; Angela Patrì; Roberta Di Caprio; Anna Balato
Journal:  Exp Ther Med       Date:  2019-09-17       Impact factor: 2.447

2.  Genome-Wide Association and Functional Studies Reveal Novel Pharmacological Mechanisms for Allopurinol.

Authors:  Deanna J Brackman; Sook Wah Yee; Osatohanmwen J Enogieru; Christian Shaffer; Dilrini Ranatunga; Joshua C Denny; Wei-Qi Wei; Yoichiro Kamatani; Michiaki Kubo; Dan M Roden; Eric Jorgenson; Kathleen M Giacomini
Journal:  Clin Pharmacol Ther       Date:  2019-05-23       Impact factor: 6.875

3.  Bone morphogenetic protein 9 overexpression reduces osteosarcoma cell migration and invasion.

Authors:  Zilan Lv; Dandan Yang; Jie Li; Min Hu; Min Luo; Xiaoqin Zhan; Peipei Song; Chen Liu; Huili Bai; Baolin Li; Yang Yang; Yingying Chen; Qiong Shi; Yaguang Weng
Journal:  Mol Cells       Date:  2013-06-25       Impact factor: 5.034

4.  The influence of genetic ancestry and ethnicity on breast cancer survival associated with genetic variation in the TGF-β-signaling pathway: The Breast Cancer Health Disparities Study.

Authors:  Martha L Slattery; Abbie Lundgreen; Marianna C Stern; Lisa Hines; Roger K Wolff; Anna R Giuliano; Kathy B Baumgartner; Esther M John
Journal:  Cancer Causes Control       Date:  2013-12-12       Impact factor: 2.506

Review 5.  New insights into BMP9 signaling in liver diseases.

Authors:  Qian-Qian Jiang; Bei-Bei Liu; Ke-Shu Xu
Journal:  Mol Cell Biochem       Date:  2021-05-21       Impact factor: 3.396

6.  Enhancing cell seeding and osteogenesis of MSCs on 3D printed scaffolds through injectable BMP2 immobilized ECM-Mimetic gel.

Authors:  Farahnaz Fahimipour; Erfan Dashtimoghadam; Mohammad Mahdi Hasani-Sadrabadi; Jessica Vargas; Daryoosh Vashaee; Douglas C Lobner; Tahereh S Jafarzadeh Kashi; Behnam Ghasemzadeh; Lobat Tayebi
Journal:  Dent Mater       Date:  2019-04-23       Impact factor: 5.304

Review 7.  Potential targeted therapy and diagnosis based on novel insight into growth factors, receptors, and downstream effectors in acute kidney injury and acute kidney injury-chronic kidney disease progression.

Authors:  Li Gao; Xiang Zhong; Juan Jin; Jun Li; Xiao-Ming Meng
Journal:  Signal Transduct Target Ther       Date:  2020-02-14

8.  Augmented BMP signaling commits cranial neural crest cells to a chondrogenic fate by suppressing autophagic β-catenin degradation.

Authors:  Jingwen Yang; Megumi Kitami; Haichun Pan; Masako Toda Nakamura; Honghao Zhang; Fei Liu; Lingxin Zhu; Yoshihiro Komatsu; Yuji Mishina
Journal:  Sci Signal       Date:  2021-01-12       Impact factor: 8.192

9.  Contextual effect of repression of bone morphogenetic protein activity in prostate cancer.

Authors:  Linda Kim Pham; Mengmeng Liang; Helty A Adisetiyo; Chun-Peng Liao; Michael B Cohen; Stanley M Tahara; Baruch Frenkel; Noriyuki Kasahara; Pradip Roy-Burman
Journal:  Endocr Relat Cancer       Date:  2013-11-04       Impact factor: 5.678

10.  Bone morphogenetic protein 2 inhibits hepatocellular carcinoma growth and migration through downregulation of the PI3K/AKT pathway.

Authors:  Ying Zheng; Xuemei Wang; Haidong Wang; Wei Yan; Quan Zhang; Xin Chang
Journal:  Tumour Biol       Date:  2014-02-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.